|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Media Contact:
Natacha Dorget
[email protected]
514-733-1998
Replicor presents final REP 401 data demonstrating persistent functional cure of HBV
MONTREAL, June 10th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for chronic hepatitis B and D patients, presented the final follow-up data from the REP 401 study assessing the impact of addition of REP 2139-Mg or REP 2165-Mg to an existing backbone therapy of TDF and pegylated interferon in participants with chronic HBeAg negative HBV infection at the 2019 Science of HBV Cure Meeting being held June 7th-8th, 2019 in Singapore.
The initial high rates of functional control and functional cure of HBV observed at 24 weeks of follow-up have persisted to the end of the scheduled 48 weeks of follow-up, with 83% of participants who completed therapy achieving functional control of their infection no longer requiring therapy under current guidelines. Moreover, 40% of participants further maintained functional cure, indicating the successful restoration of strong immunological control of their chronic HBV infection in the absence of therapy. Additionally, 91% of patients have maintained persistently normal liver function with overall reversal of liver inflammation and fibrosis, now normal (as assessed by liver stiffness) in 57% of participants.
Meta-analysis of all HBeAg negative patients in the previous REP 301 and the current REP 401 trials revealed that the extent of transaminase flare activity occurring when HBsAg was < 1 IU/mL predicted virologic outcomes; increased flare activity while HBsAg was < 1 IU/mL increased the likelihood of establishing functional control and functional cure.
Replicor’s presentation is now available on the company’s website at www.replicor.com/science/conference-presentations. For further information about the 2019 Science of HBV Cure Meeting: https://www.scienceofhbvcure.com/. |
|
发表于 2019-6-11 13:12
